You searched for "outcomes"
Intravitreal triamcinolone for uveitic macular oedema
1 June 2016
| Saruban Pasu
|
EYE - Vitreo-Retinal
This paper from South Korea reports on a prospective, double blind, randomised clinical study designed to evaluate the additional benefit of intravitreal triamcinolone (TA) administration for noninfectious uveitic macular oedema as an adjunct therapy to systemic anti-inflammatory treatment. Patients were...
Association between serum levels of testosterone and estradiol with meibomian gland assessments in postmenopausal women
This study aims to reveal any correlation between serum levels of testosterone and estradiol in postmenopausal women with meibomian gland dysfunction. Postmenopausal subjects were defined as amenorrhoea for at least one year with low follide stimulating hormone (FSH) and estradiol....Subfoveal choroidal thickness and PCV
1 April 2018
| Saruban Pasu
|
EYE - Vitreo-Retinal
This report studies the prognostic factors for visual improvement and the need for additional treatments at one year after the initial combination therapy of intravitreal ranibizumab injection or intravitreal aflibercept injection followed by PDT in eyes with PCV. Fifty-six eyes...
Phaco-ECP vs. Phaco alone to treat glaucoma
1 December 2015
| Anjali Gupta
|
EYE - Glaucoma
This retrospective review compared combined phacoemulsification and endoscopic cyclophotocoagulation (phaco-ECP) to phaco alone in patients with mild to moderate glaucoma. Outcome measures included cumulative full and qualified success survival, postintervention IOP and ocular anti-hypertensive medication reduction. Full success was defined...
ARN in North Africa
1 December 2015
| Saruban Pasu
|
EYE - Vitreo-Retinal
Acute retinal necrosis (ARN) is a rare cause of uveitis. This paper aims to outline the clinical features of 12 patients with ARN in a referral centre in Tunisia, North Africa. A retrospective review of case notes was carried out....
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
1 April 2015
| Jonathan CP Roos
|
EYE - Vitreo-Retinal
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
Meta-analysis of HLA B27 associated acute anterior uveitis
1 August 2018
| Mrinal Rana
|
EYE - Vitreo-Retinal
A literature-based meta-analysis was carried out to look at the various clinical features associated with HLA- B27 acute anterior uveitis (AAU). After an extensive search of literature for HLA B27 uveitis was conducted, 735 results were obtained. Twenty-nine articles were...
Intracameral bevacizumab as an adjunct to trabeculectomy
This is a 12-month, prospective, randomised, double-masked, placebo-controlled trial of patients who were not controlled medically with open angle glaucoma and scheduled for a primary trabeculectomy. Patients were recruited and randomised during the period between April 2009 and November 2010....Direct endoscopic probing for congenital lacrimal duct obstruction
1 April 2014
| Anjali Gupta
|
EYE - General
The most common treatment for congenital lacrimal duct obstruction (CLDO) is probing, which is traditionally a blind procedure. Previous literature reports success rates between 78-92%. The authors of this retrospective non comparative case series reviewed the success rates of probing...
PRN Ranibizumab verses continuous aflibercept in UK clinical practice
1 October 2018
| Jonathan Chan
|
EYE - Vitreo-Retinal
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...
Moxifloxacin 0.5% for bacterial keratitis
The authors report on the results of a randomised controlled trial comparing commercially available non-preserved moxifloxacin 0.5% vs. a combination of fortified cefazolin 5% and tobramycin 1.3% in the treatment of moderate bacterial keratitis without perforation. Corneal scrapings were collected...Features of Behcet’s disease
1 April 2019
| Jonathan Chan
|
EYE - Neuro-ophthalmology
|
imaging, immunology, inflammation, optic erve
This is a retrospective single centre study from Paris, France, between the periods of 1986 to 2015. Twenty-nine out of 217 (13.3%) neuro-Behcet’s disease (NBD) patients presented with neuro-ophthalmic manifestations (55% of men and mean age of 28 years). Sixteen...